The estimated Net Worth of Asset Management, Lp Chen B... is at least $314 Million dollars as of 23 October 2023. Asset B owns over 1,307,311 units of Ambrx Biopharma stock worth over $314,468,000 and over the last 2 years Asset sold AMAM stock worth over $0.
Asset has made over 5 trades of the Ambrx Biopharma stock since 2023, according to the Form 4 filled with the SEC. Most recently Asset bought 1,307,311 units of AMAM stock worth $9,138,104 on 23 October 2023.
The largest trade Asset's ever made was buying 5,215,189 units of Ambrx Biopharma stock on 18 April 2023 worth over $58,931,636. On average, Asset trades about 2,454,627 units every 45 days since 2023. As of 23 October 2023 Asset still owns at least 11,231,000 units of Ambrx Biopharma stock.
You can see the complete history of Asset B stock trades at the bottom of the page.
Over the last 2 years, insiders at Ambrx Biopharma have traded over $616,598 worth of Ambrx Biopharma stock and bought 12,273,134 units worth $123,242,196 . The most active insiders traders include Asset Management, Lp Chen B..., Daniel J. O'connor, and Paul V Maier. On average, Ambrx Biopharma executives and independent directors trade stock every 32 days with the average trade being worth of $49,343,700. The most recent stock trade was executed by Sonja Nelson on 27 October 2023, trading 12,778 units of AMAM stock currently worth $125,480.
Ambrx Biopharma executives and other stock owners filed with the SEC include: